Clinical Trials Directory

Trials / Completed

CompletedNCT05360862

Prone Positioning and R/I Ratio in COVID-19 Patients With ARDS (SyDRAC-DV)

Effects of Prone Positioning-induced on the Recruitment-to-inflation Ratio in COVID-19 Patients With Acute Respiratory Distress Syndrome

Status
Completed
Phase
Study type
Observational
Enrollment
92 (actual)
Sponsor
Centre Hospitalier Universitaire de Nice · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine the efects of prone positioning on the recruitment- to-inflation ratio in COVID-19 patients with acute respiratory distress syndrome.

Detailed description

High positive end-expiratory pressure (PEEP) level and prone positioning (PP) are recommended in patients with moderate to severe acute respiratory distress syndrome (ARDS) in order to recruit lung and thus to improve oxygenation. Thus, high PEEP level and prone positioning will be more effective in patients with high potential for lung recruitment. Recently, the Recruitment-to-Inflation Ratio (R/I ratio) has been described and validated in patients with ARDS to estimate the potential for lung recruitment. In this regard, the R/I ration may be of interest to titrate PEEP level in patients with ARDS. This would be of particular interest in COVID-19 patients with ARDS, since different ARDS phenotypes with heterogeneous potential of lung recruitment have been described in these patients. However, the effects of prone positioning on R/I ratio have been scarcely described so far. Thus, the main goal of this study is to investigate the effects of prone positioning on the R/I ratio in COVID-19 patients with ARDS. The second goal of this study is to determine the effects of prone positioning on oxygenation and respiratory mechanics according to the R/I ratio.

Conditions

Interventions

TypeNameDescription
PROCEDUREProne positioning sessionTo perform respiratory measurements before, during and after a prone positioning session.

Timeline

Start date
2022-11-03
Primary completion
2023-09-29
Completion
2023-09-29
First posted
2022-05-04
Last updated
2024-02-08

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT05360862. Inclusion in this directory is not an endorsement.